Sorafenib alone versus Sorafenib combined with Gemcitabine and Oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final analysis of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study)

被引：0
|
作者：
Assenat, E. [1 ]
Boige, V. [2 ]
Thezenas, S. [3 ]
Pageaux, G. P. [4 ]
Perron, J. M. [5 ]
Becouarn, Y. [6 ]
Seitz, J. F. [7 ]
Merle, P. H. [8 ]
Blanc, J. F. [9 ]
Ychou, M. [10 ]
机构：
[1] Univ Hosp Montpellier, Montpellier 05, France
[2] IGR Canc Ctr, Villejuif, France
[3] ICM Canc Ctr, Montpellier, France
[4] CHU St Eloi, Montpellier, France
[5] CHU, Toulouse, France
[6] Inst Bergonier, Bordeaux, France
[7] CHU La Timone, Marseille, France
[8] CHU, Lyon, France
[9] CHU St Andre, Bordeaux, France
[10] ICM Canc Ctr, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2467
引用
收藏
页码：S578 / S578
页数：1
相关论文
共 50 条
  • [31] Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
    Kondo, Masaaki
    Morimoto, Manabu
    Kobayashi, Satoshi
    Ohkawa, Shinichi
    Hidaka, Hisashi
    Nakazawa, Takahide
    Aikata, Hiroshi
    Hatanaka, Takeshi
    Takizawa, Daichi
    Matsunaga, Kotaro
    Okuse, Chiaki
    Suzuki, Michihiro
    Taguri, Masataka
    Ishibashi, Takako
    Numata, Kazushi
    Maeda, Shin
    Tanaka, Katsuaki
    BMC CANCER, 2019, 19 (01)
  • [32] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Fanizzi, Annarita
    Massafra, Raffaella
    De Luca, Raffaele
    Brandi, Giovanni
    CURRENT ONCOLOGY, 2023, 30 (01) : 749 - 757
  • [34] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma and the predictive effect and correlation of CTC
    Xu, L.
    Che, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S596 - S596
  • [36] Gemcitabine and oxaliplatin (GEMOX) as first-line chemotherapy in advanced biliary tract adenocarcinoma:: Preliminary results of a phase II study
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Petricola, F.
    Calabro, P.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
  • [37] SUBGROUP ANALYSIS AND UPDATED RESULTS OF A RANDOMIZED STUDY COMPARING SORAFENIB PLUS INTERLEUKIN-2 VERSUS SORAFENIB ALONE AS FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA
    Procopio, Giuseppe
    Verzoni, Elena
    Bracarda, Sergio
    Conti, Giario
    Guadalupi, Valentina
    Ortega, Cinzia
    Nicolai, Nicola
    Torelli, Tullio
    Bajetta, Emilio
    Salvioni, Roberto
    ANTICANCER RESEARCH, 2010, 30 (04) : 1461 - 1462
  • [38] Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Szczylik, Cezary
    Hutson, Thomas E.
    Demkow, Tomasz
    Staehler, Michael
    Rolland, Frederic
    Negrier, Sylvie
    Laferriere, Nicole
    Scheuring, Urban J.
    Cella, David
    Shah, Sonalee
    Bukowski, Ronald M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1280 - 1289
  • [39] A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
    Lin, Zhong-Zhe
    Chen, Bang-Bin
    Hung, Yi-Ping
    Huang, Po-Hsiang
    Shen, Ying-Chun
    Shao, Yu-Yun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Lee, Rheun-Chuan
    Chao, Yee
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (09): : E1280 - E1285
  • [40] Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    He, Aiwu Ruth
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Hung, Chao-Hung
    Sheen, I-Shyan
    Izumi, Namiki
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Shiratori, Shinichi
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 896 - 904
12345